<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="8cb6cfed-487e-4351-8f48-0be3cc5c2d6d"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use <content styleCode="bold">FYLNETRA</content> safely and effectively. See full prescribing information for <content styleCode="bold">FYLNETRA</content>.</content>
      <br/>
      <br/>
      <content styleCode="bold">FYLNETRA<sup>®</sup> (pegfilgrastim-pbbk</content>
      <content styleCode="bold">) injection, for subcutaneous use<br/>
Initial U.S. Approval: 2022
<br/>
         <br/>
      </content>FYLNETRA (pegfilgrastim-pbbk) is biosimilar* to NEULASTA (pegfilgrastim).</title>
   <effectiveTime value="20250425"/>
   <setId root="eeadd641-573d-47fe-897a-61006e5f9e03"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="827748190" root="1.3.6.1.4.1.519.1"/>
            <name>Amneal Pharmaceuticals LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="927408919" root="1.3.6.1.4.1.519.1"/>
                        <name>Kashiv BioSciences, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1627" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1627" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="095aafbb-b2e7-48da-9917-d81ee0aac294"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250425"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70121-1627" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>FYLNETRA</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>pegfilgrastim</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="6"/>
                              <denominator unit="mL" value="0.6"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3A58010674" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEGFILGRASTIM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="3A58010674" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PEGFILGRASTIM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.36"/>
                              <denominator unit="mL" value="0.6"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="mL" value="0.6"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.02"/>
                              <denominator unit="mL" value="0.6"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.03"/>
                              <denominator unit="mL" value="0.6"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.6"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" displayName="SYRINGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70121-1627-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220531"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761084" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220531"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_ff778b92-c2ea-4476-b361-dd4ea39d25f0">
               <id root="cb2616ec-fab8-45f9-a2a8-29bd303844ae"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>
                  <br/>
               </title>
               <text>
                  <br/>
               </text>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Indications and Usage, Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome <linkHtml href="#LINK_ec358c95-b5ef-47cc-ad8e-7437cda275ac">(1.2)</linkHtml>                         04/2025</paragraph>
                        <paragraph>Dosage and Administration, Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome <linkHtml href="#LINK_e235ef97-543a-4bc2-b608-e0191d07c062">(2.2)</linkHtml>                  04/2025</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_dcc7625b-a191-4f48-8146-292d94488a99">
               <id root="57464155-c100-4839-b817-c914285a209f"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text/>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>FYLNETRA is a leukocyte growth factor indicated to </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. <linkHtml href="#LINK_3141cc77-6fb4-459d-b781-f3cbd30fe41f">(1.1)</linkHtml>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). <linkHtml href="#LINK_ec358c95-b5ef-47cc-ad8e-7437cda275ac">(1.2)</linkHtml>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">
                              <br/>
Limitations of Use</content>
                        </paragraph>
                        <paragraph>FYLNETRA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_3141cc77-6fb4-459d-b781-f3cbd30fe41f">
                     <id root="c80715da-2d5f-4237-9aeb-60d512524523"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy</title>
                     <text>
                        <paragraph>FYLNETRA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_70f35532-d0a6-4765-a114-c6afe5a273f4">Clinical Studies (14.1)</linkHtml>]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>FYLNETRA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ec358c95-b5ef-47cc-ad8e-7437cda275ac">
                     <id root="00fe2418-404b-43a7-a5a2-f575899a32a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Patients with Hematopoietic Subsyndrome of
Acute Radiation Syndrome</title>
                     <text>
                        <paragraph>FYLNETRA is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation <content styleCode="italics">[see <linkHtml href="#LINK_e235ef97-543a-4bc2-b608-e0191d07c062">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#LINK_a56f3df3-d9b5-4454-b846-63c97966a36a">Clinical Studies (14.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d92f1989-a9d2-4cca-8a85-96d41249ba17">
               <id root="fbf3e18d-fa3e-430f-876e-c110570ea6e6"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with cancer receiving myelosuppressive chemotherapy </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>6 mg administered subcutaneously once per chemotherapy cycle. <linkHtml href="#LINK_7d5255b1-436d-4d41-b31c-4be2d16a2c70">(2.1)</linkHtml> </item>
                           <item>Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy. <linkHtml href="#LINK_7d5255b1-436d-4d41-b31c-4be2d16a2c70">(2.1)</linkHtml> </item>
                           <item>Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. <linkHtml href="#LINK_6cab6be9-52a8-4ee3-93c0-ccae68b39b4f">(2.3)</linkHtml>
                           </item>
                        </list>
                        <paragraph>Patients acutely exposed to myelosuppressive doses of radiation</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Two doses, 6 mg each, administered subcutaneously one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation, and a second dose one week after. <linkHtml href="#LINK_e235ef97-543a-4bc2-b608-e0191d07c062">(2.2)</linkHtml>
                           </item>
                           <item>Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. <linkHtml href="#LINK_6cab6be9-52a8-4ee3-93c0-ccae68b39b4f">(2.3)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_7d5255b1-436d-4d41-b31c-4be2d16a2c70">
                     <id root="930dd2b5-8cf4-43ea-bb1f-c4ff67f2e414"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Patients with Cancer Receiving
Myelosuppressive Chemotherapy</title>
                     <text>
                        <paragraph>The recommended dosage of FYLNETRA is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle. For dosing in pediatric patients weighing less than 45 kg, refer to Table 1. Do not administer FYLNETRA between 14 days before and 24 hours after administration of cytotoxic chemotherapy.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e235ef97-543a-4bc2-b608-e0191d07c062">
                     <id root="0d87e943-d9ab-416d-8b78-4ca0edbd5218"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Patients
with Hematopoietic Subsyndrome of Acute Radiation  Syndrome</title>
                     <text>
                        <paragraph>The recommended dose of FYLNETRA is two doses, 6 mg each, administered subcutaneously one week apart. For dosing in pediatric patients weighing less than 45 kg, refer to Table 1. Administer the first dose as soon as possible after suspected or confirmed exposure to radiation levels greater than 2 gray (Gy). Administer the second dose one week after the first dose. </paragraph>
                        <paragraph>Obtain a baseline complete blood count (CBC). Do not delay administration of FYLNETRA if a CBC is not readily available. Estimate a patient’s absorbed radiation dose (i.e., level of radiation exposure) based on information from public health authorities, biodosimetry if available, or clinical findings such as time to onset of vomiting or lymphocyte depletion kinetics.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6cab6be9-52a8-4ee3-93c0-ccae68b39b4f">
                     <id root="549114a3-bb35-49c5-aa09-49708ecb786c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Administration</title>
                     <text>
                        <paragraph>FYLNETRA is administered subcutaneously via a single-dose prefilled syringe for manual use.</paragraph>
                        <paragraph>Prior to use‚ remove the carton from the refrigerator and allow the FYLNETRA prefilled syringe to reach room temperature for a minimum of 30 minutes. Discard any prefilled syringe left at room temperature for greater than 72 hours.</paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer FYLNETRA if discoloration or particulates are observed.</paragraph>
                        <paragraph>The needle cap on the prefilled syringe is not made with natural rubber latex.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients weighing less than 45 kg</content>
                        </paragraph>
                        <paragraph>The FYLNETRA prefilled syringe is not designed to allow for direct administration of doses less than 0.6 mL (6 mg). The syringe does not bear graduation marks, which are necessary to accurately measure doses of FYLNETRA less than 0.6 mL (6 mg) for direct administration to patients. Thus, the direct administration to patients requiring dosing of less than 0.6 mL (6 mg) is not recommended due to the potential for dosing errors. Refer to Table 1.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1. Dosing of </content>
                           <content styleCode="bold">FYLNETRA</content>
                           <content styleCode="bold"> for pediatric patients weighing less than 45 kg</content>
                        </paragraph>
                        <table width="865px" cellspacing="0" cellpadding="0" border="1">
                           <col width="1pt"/>
                           <col width="215.578px"/>
                           <col width="244.484px"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Body Weight</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">FYLNETRA Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Volume to Administer</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Less than 10 kg<content styleCode="bold">*</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>See below<content styleCode="bold">*</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>See below<content styleCode="bold">*</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>10 to 20 kg</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1.5 mg</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.15 mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>21 to 30 kg</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2.5 mg</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.25 mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>31 to 44 kg</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4 mg</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.4 mL</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>*For pediatric patients weighing less than 10 kg, administer 0.1 mg/kg (0.01 mL/kg) of FYLNETRA.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5c9c0310-95ff-4c99-8501-bfa96977bd0e">
               <id root="176b4f44-a9fd-48e9-8e73-de3313fe7b81"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>FYLNETRA is a clear, colorless to slightly yellow, preservative-free solution available as:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only. </item>
                  </list>
               </text>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 6 mg/0.6 mL solution in a single-dose prefilled syringe for manual use only. <linkHtml href="#LINK_5c9c0310-95ff-4c99-8501-bfa96977bd0e">(3)</linkHtml> </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_35607910-9126-475d-9b48-deb0730399c6">
               <id root="768f461a-9b5e-4d1d-b353-38e7e1a3fccf"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>FYLNETRA is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_673b0241-59f9-482a-aac5-31f5d2108c37">Warnings and Precautions (5.3)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim products or filgrastim products. <linkHtml href="#LINK_35607910-9126-475d-9b48-deb0730399c6">(4)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_9128fa83-4e1b-4064-9176-04dcbbcef29e">
               <id root="02dacf29-eeb3-4c1b-b21f-1d478dba9e2d"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.<linkHtml href="#LINK_0137782b-84c3-452c-81d6-57dd909b5f28">(5.1)</linkHtml>
                           </item>
                           <item>Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue FYLNETRA in patients with ARDS. <linkHtml href="#LINK_a83cd74a-0639-4e21-b956-d4c31c27a55b">(5.2)</linkHtml> </item>
                           <item>Serious allergic reactions, including anaphylaxis: Permanently discontinue FYLNETRA in patients with serious allergic reactions. <linkHtml href="#LINK_673b0241-59f9-482a-aac5-31f5d2108c37">(5.3)</linkHtml> </item>
                           <item>Fatal sickle cell crises: Discontinue FYLNETRA if sickle cell crisis occurs. <linkHtml href="#LINK_70ab941c-2d5d-4d44-830d-22afc84a4503">(5.4)</linkHtml> </item>
                           <item>Glomerulonephritis: Evaluate and consider dose-reduction or interruption of FYLNETRA if causality is likely. <linkHtml href="#LINK_5895e635-5ba2-4e66-8caa-55761ea99882">(5.5)</linkHtml> </item>
                           <item>Thrombocytopenia: Monitor platelet counts. <linkHtml href="#LINK_af80e92b-61e2-41c0-a4c8-d362567990d8">(5.7)</linkHtml>
                           </item>
                           <item>Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): Monitor patients with breast and lung cancer using FYLNETRA in conjunction with chemotherapy and/or radiotherapy for signs and symptoms of MDS/AML. <linkHtml href="#LINK_96c85477-3454-4267-bb22-eeaa0760e91d">(5.10)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_0137782b-84c3-452c-81d6-57dd909b5f28">
                     <id root="1f2e720c-cb6d-4245-852b-6596a512191a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Splenic Rupture</title>
                     <text>
                        <paragraph>Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products. Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving FYLNETRA.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a83cd74a-0639-4e21-b956-d4c31c27a55b">
                     <id root="af6a5803-ccfb-44a3-99c1-8ba0a46ffcef"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Acute Respiratory Distress Syndrome</title>
                     <text>
                        <paragraph>Acute respiratory distress syndrome (ARDS) can occur in patients receiving pegfilgrastim products. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving FYLNETRA, for ARDS. Discontinue FYLNETRA in patients with ARDS.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_673b0241-59f9-482a-aac5-31f5d2108c37">
                     <id root="da9438b7-eb7b-4aa1-8f2b-2a6343bd1722"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Serious Allergic Reactions</title>
                     <text>
                        <paragraph>Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products. The majority of reported events occurred upon initial exposure. Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue FYLNETRA in patients with serious allergic reactions. Do not administer FYLNETRA to patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_70ab941c-2d5d-4d44-830d-22afc84a4503">
                     <id root="1722c6e9-3b57-4cf6-820b-899085275b69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Use in Patients with Sickle Cell
Disorders</title>
                     <text>
                        <paragraph>Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products. Discontinue FYLNETRA if sickle cell crisis occurs.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5895e635-5ba2-4e66-8caa-55761ea99882">
                     <id root="79f6e536-d186-452d-838c-e1e90bd439fc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Glomerulonephritis</title>
                     <text>
                        <paragraph>Glomerulonephritis has occurred in patients receiving pegfilgrastim products. The diagnoses were based upon azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events of glomerulonephritis resolved after dose-reduction or discontinuation of pegfilgrastim products. If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of FYLNETRA.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c131171d-4101-4988-bc0a-65f2f26218c5">
                     <id root="94197103-cf2d-4e26-9ef5-6ce6eb8ff2bf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Leukocytosis</title>
                     <text>
                        <paragraph>White blood cell (WBC) counts of 100 x 10<sup>9</sup>/L or greater have been observed in patients receiving pegfilgrastim products. Monitoring of complete blood count (CBC) during FYLNETRA therapy is recommended.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_af80e92b-61e2-41c0-a4c8-d362567990d8">
                     <id root="510138ef-4552-4ce7-80b4-5600b20a98d3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Thrombocytopenia</title>
                     <text>
                        <paragraph>Thrombocytopenia has been reported in patients receiving pegfilgrastim products. Monitor platelet counts.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_89151889-9cbc-49dc-94a2-e6b8e6b56806">
                     <id root="ed9a4679-62d3-40a1-becb-955e71a18171"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Capillary Leak Syndrome</title>
                     <text>
                        <paragraph>Capillary leak syndrome has been reported after G-CSF administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration. Episodes vary in frequency, severity and may be life-threatening if treatment is delayed. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_24a58db1-3a55-453f-b6c1-372ef936041c">
                     <id root="7f7cf250-8731-44bb-b988-6d6af75c4437"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Potential for Tumor Growth Stimulatory
Effects on Malignant Cells</title>
                     <text>
                        <paragraph>The granulocyte colony-stimulating factor (G-CSF) receptor through which pegfilgrastim products and filgrastim products act has been found on tumor cell lines. The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_96c85477-3454-4267-bb22-eeaa0760e91d">
                     <id root="9d7433e6-cf1a-4624-bba2-74954fb60b6f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Myelodysplastic
Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and
Lung Cancer</title>
                     <text>
                        <paragraph>MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cf057c7e-8e29-4952-9649-bbf6de6949b0">
                     <id root="ae1a491b-a961-4b70-9173-4c0ce9cd2b4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Aortitis</title>
                     <text>
                        <paragraph>Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy. Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count). Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue FYLNETRA if aortitis is suspected.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_69e665a7-53ee-4ac5-8d54-84fc176e9bc9">
                     <id root="cce34223-2426-4690-8474-2b473deb4ed8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Nuclear
Imaging</title>
                     <text>
                        <paragraph>Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e4516829-3372-4889-a323-a0dffe06c930">
               <id root="78de10a5-cd90-4083-abe6-b35420bbee85"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Splenic Rupture <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_0137782b-84c3-452c-81d6-57dd909b5f28">Warnings and Precautions (5.1)</linkHtml>] </content>
                     </item>
                     <item>Acute Respiratory Distress Syndrome <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_a83cd74a-0639-4e21-b956-d4c31c27a55b">Warnings and Precautions (5.2)</linkHtml>] </content>
                     </item>
                     <item>Serious Allergic Reactions <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_673b0241-59f9-482a-aac5-31f5d2108c37">Warnings and Precautions (5.3)</linkHtml>] </content>
                     </item>
                     <item>Use in Patients with Sickle Cell Disorders <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_70ab941c-2d5d-4d44-830d-22afc84a4503">Warnings and Precautions (5.4)</linkHtml>] </content>
                     </item>
                     <item>Glomerulonephritis <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_5895e635-5ba2-4e66-8caa-55761ea99882">Warnings and Precautions (5.5)</linkHtml>] </content>
                     </item>
                     <item>Leukocytosis <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_c131171d-4101-4988-bc0a-65f2f26218c5">Warnings and Precautions (5.6)</linkHtml>] </content>
                     </item>
                     <item>Thrombocytopenia <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_af80e92b-61e2-41c0-a4c8-d362567990d8">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Capillary Leak Syndrome <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_89151889-9cbc-49dc-94a2-e6b8e6b56806">Warnings and Precautions (5.8)</linkHtml>] </content>
                     </item>
                     <item>Potential for Tumor Growth Stimulatory Effects on Malignant Cells <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_24a58db1-3a55-453f-b6c1-372ef936041c">Warnings and Precautions (5.9)</linkHtml>]</content>
                     </item>
                     <item>Myelodysplastic Syndrome <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_96c85477-3454-4267-bb22-eeaa0760e91d">Warnings and Precautions (5.10)</linkHtml>]</content>
                     </item>
                     <item>Acute Myeloid Leukemia <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_96c85477-3454-4267-bb22-eeaa0760e91d">Warnings and Precautions (5.10)</linkHtml>]</content>
                     </item>
                     <item>Aortitis<content styleCode="italics"> [see <linkHtml href="#www.splportal.comLINK_cf057c7e-8e29-4952-9649-bbf6de6949b0">Warnings and Precautions (5.11)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity. <linkHtml href="#LINK_e2741247-5b1d-49aa-9b48-6be56a69b90f">(6.1)</linkHtml>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835 5472, option 3 or FDA at 1-800-FDA-1088 or<content styleCode="italics">
                                 <content styleCode="underline"> www.fda.gov/medwatch.</content>
                              </content>
                           </content>
                        </paragraph>
                        <paragraph>* Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of  FYLNETRA<sup>®</sup> has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_e2741247-5b1d-49aa-9b48-6be56a69b90f">
                     <id root="bec4cdc0-cf4f-43de-8a4c-03bd7ffff403"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>Pegfilgrastim clinical trials safety data are based upon 932 patients receiving pegfilgrastim in seven randomized clinical trials. The population was 21 to 88 years of age and 92% female. The ethnicity was 75% Caucasian, 18% Hispanic, 5% Black, and 1% Asian. Patients with breast (n = 823), lung and thoracic tumors (n = 53) and lymphoma (n = 56) received pegfilgrastim after nonmyeloablative cytotoxic chemotherapy. Most patients received a single 100 mcg/kg (n = 259) or a single 6 mg (n = 546) dose per chemotherapy cycle over 4 cycles.</paragraph>
                        <paragraph>The following adverse reaction data in Table 2 are from a randomized, double-blind, placebo-controlled study in patients with metastatic or non-metastatic breast cancer receiving docetaxel 100 mg/m<sup>2</sup> every 21 days (Study 3). A total of 928 patients were randomized to receive either 6 mg pegfilgrastim (n = 467) or placebo (n = 461). The patients were 21 to 88 years of age and 99% female. The ethnicity was 66% Caucasian, 31% Hispanic, 2% Black, and &lt; 1% Asian, Native American, or other.</paragraph>
                        <paragraph>The most common adverse reactions occurring in ≥ 5% of patients and with a between-group difference of ≥ 5% higher in the pegfilgrastim arm in placebo-controlled clinical trials are bone pain and pain in extremity.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2. Adverse Reactions with ≥ 5% Higher Incidence in pegfilgrastim Patients Compared to Placebo in Study 3</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="1">
                           <col width="1pt"/>
                           <col width="14.64%"/>
                           <col width="36.98%"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Body System</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N= 461)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Pegfilgrastim 6 mg SC on Day 2</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N= 467)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Musculoskeletal and connective tissue disorders</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Bone pain </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>26%</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>31%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Pain in extremity </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Leukocytosis </content>
                        </paragraph>
                        <paragraph>In clinical studies, leukocytosis (WBC counts &gt; 100 x 10<sup>9</sup>/L) was observed in less than 1% of 932 patients with non-myeloid malignancies receiving pegfilgrastim. No complications attributable to leukocytosis were reported in clinical studies.</paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_fe4f430a-3d93-46a6-aa41-0cadfc3888c6">
                     <id root="5bf93d9e-f09b-4ef5-bcf3-e27af9968032"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Immunogenicity</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of pegfilgrastim or of other pegfilgrastim products.</paragraph>
                        <paragraph>Binding antibodies to pegfilgrastim were detected using a BIAcore assay. The approximate limit of detection for this assay is 500 ng/mL. Pre-existing binding antibodies were detected in approximately 6% (51/849) of patients with metastatic breast cancer. Four of 521 pegfilgrastim-treated subjects who were negative at baseline developed binding antibodies to pegfilgrastim following treatment. None of these 4 patients had evidence of neutralizing antibodies detected using a cell-based bioassay.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_da963bb1-a654-4ef1-8f29-2ec8630252f1">
                     <id root="460cc93b-714b-4897-817d-48a40397e5a8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.3 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of pegfilgrastim products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Splenic rupture and splenomegaly (enlarged spleen) <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_0137782b-84c3-452c-81d6-57dd909b5f28">Warnings and Precautions (5.1)</linkHtml>]</content>
                           </item>
                           <item>Acute respiratory distress syndrome (ARDS)<content styleCode="italics"> [see <linkHtml href="#www.splportal.comLINK_a83cd74a-0639-4e21-b956-d4c31c27a55b">Warnings and Precautions (5.2)</linkHtml>]</content>
                           </item>
                           <item>Allergic reactions/hypersensitivity, including anaphylaxis, skin rash, urticaria, generalized erythema, and flushing <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_673b0241-59f9-482a-aac5-31f5d2108c37">Warnings and Precautions (5.3)</linkHtml>]</content>
                           </item>
                           <item>Sickle cell crisis <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_70ab941c-2d5d-4d44-830d-22afc84a4503">Warnings and Precautions (5.4)</linkHtml>]</content>
                           </item>
                           <item>Glomerulonephritis <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_5895e635-5ba2-4e66-8caa-55761ea99882">Warnings and Precautions (5.5)</linkHtml>]</content>
                           </item>
                           <item>Leukocytosis <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_c131171d-4101-4988-bc0a-65f2f26218c5">Warnings and Precautions (5.6)</linkHtml>]</content>
                           </item>
                           <item>Thrombocytopenia <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_af80e92b-61e2-41c0-a4c8-d362567990d8">Warnings and Precautions (5.7)</linkHtml>]</content>
                           </item>
                           <item>Capillary Leak Syndrome <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_89151889-9cbc-49dc-94a2-e6b8e6b56806">Warnings and Precautions (5.8)</linkHtml>]</content>
                           </item>
                           <item>Injection site reactions</item>
                           <item>Sweet’s syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis</item>
                           <item>Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_96c85477-3454-4267-bb22-eeaa0760e91d">Warnings and Precautions (5.10)</linkHtml>]</content>
                           </item>
                           <item>Aortitis <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_cf057c7e-8e29-4952-9649-bbf6de6949b0">Warnings and Precautions (5.11)</linkHtml>]</content>
                           </item>
                           <item>Alveolar hemorrhage</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_30a17840-3273-46f6-8ca1-5882210b0a62">
               <id root="a4d086ff-4693-409f-a871-139ea977b080"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250425"/>
               <component>
                  <section ID="LINK_c2bd2a92-f779-4d19-b7ca-ae1fc5ba098a">
                     <id root="06a0850d-95ed-4e65-b51a-62363818266d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Although available data with FYLNETRA or pegfilgrastim product use in pregnant women are insufficient to establish whether there is a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, there are available data from published studies in pregnant women exposed to filgrastim products. These studies have not established an association of filgrastim product use during pregnancy with major birth defects, miscarriage, or adverse maternal or fetal outcomes.</paragraph>
                        <paragraph>In animal studies, no evidence of reproductive/developmental toxicity occurred in the offspring of pregnant rats that received cumulative doses of pegfilgrastim approximately 10 times the recommended human dose (based on body surface area). In pregnant rabbits, increased embryolethality and spontaneous abortions occurred at 4 times the maximum recommended human dose simultaneously with signs of maternal toxicity <content styleCode="italics">(see Data)</content>.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"> </content>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Pregnant rabbits were dosed with pegfilgrastim subcutaneously every other day during the period of organogenesis. At cumulative doses ranging from the approximate human dose to approximately 4 times the recommended human dose (based on body surface area), the treated rabbits exhibited decreased maternal food consumption, maternal weight loss, as well as reduced fetal body weights and delayed ossification of the fetal skull; however, no structural anomalies were observed in the offspring from either study. Increased incidences of post-implantation losses and spontaneous abortions (more than half the pregnancies) were observed at cumulative doses approximately 4 times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose.</paragraph>
                        <paragraph>Three studies were conducted in pregnant rats dosed with pegfilgrastim at cumulative doses up to approximately 10 times the recommended human dose at the following stages of gestation: during the period of organogenesis, from mating through the first half of pregnancy, and from the first trimester through delivery and lactation. No evidence of fetal loss or structural malformations was observed in any study. Cumulative doses equivalent to approximately 3 and 10 times the recommended human dose resulted in transient evidence of wavy ribs in fetuses of treated mothers (detected at the end of gestation but no longer present in pups evaluated at the end of lactation).</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_83aa7b7d-cbc3-4fae-bd22-40fdc6826d04">
                     <id root="0488f931-cc7c-4a3e-b2d5-1d1f3ab30a29"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of pegfilgrastim products in human milk, the effects on the breastfed child, or the effects on milk production. Other filgrastim products are secreted poorly into breast milk, and filgrastim products are not absorbed orally by neonates. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for FYLNETRA and any potential adverse effects on the breastfed child from FYLNETRA or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_036982a3-77c0-4b49-8808-7c7677b6721a">
                     <id root="d0aeec90-9a90-48bb-9974-157ee42c6af8"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of FYLNETRA have been established in pediatric patients. No overall differences in safety were identified between adult and pediatric patients based on postmarketing surveillance and review of the scientific literature.</paragraph>
                        <paragraph>Use of FYLNETRA in pediatric patients for chemotherapy-induced neutropenia is based on adequate and well-controlled studies of pegfilgrastim in adults with additional pharmacokinetic and safety data of pegfilgrastim in pediatric patients with sarcoma <content styleCode="italics">[</content>
                           <content styleCode="italics">see <linkHtml href="#www.splportal.comLINK_f6632b0b-4703-4103-b11f-55e7f153f562">Clinical Pharmacology (12.3)</linkHtml> </content>and<content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_70f35532-d0a6-4765-a114-c6afe5a273f4">Clinical Studies (14.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>The use of FYLNETRA to increase survival in pediatric patients acutely exposed to myelosuppressive doses of radiation is based on efficacy studies of pegfilgrastim conducted in animals and clinical data supporting the use of pegfilgrastim in patients with cancer receiving myelosuppressive chemotherapy. Efficacy studies of pegfilgrastim products could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Results from population modeling and simulation indicate that two doses of pegfilgrastim (Table 1), administered one week apart provide pediatric patients with exposures comparable to that in adults receiving two 6 mg doses one week apart <content styleCode="italics">[see <linkHtml href="#LINK_6cab6be9-52a8-4ee3-93c0-ccae68b39b4f">Dosage and Administration (2.3)</linkHtml>, <linkHtml href="#LINK_f6632b0b-4703-4103-b11f-55e7f153f562">Clinical Pharmacology (12.3)</linkHtml> and <linkHtml href="#LINK_a56f3df3-d9b5-4454-b846-63c97966a36a">Clinical Studies (14.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3f19635f-4e9f-4316-8666-df712cbe0b78">
                     <id root="dd1a7f2f-5d11-4243-9226-b4c58158411e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 932 patients with cancer who received pegfilgrastim in clinical studies, 139 (15%) were aged 65 and over, and 18 (2%) were aged 75 and over. No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b1fe35df-8558-420e-a757-62d6b55b90fb">
               <id root="88cb2c34-efc3-4924-9c09-f51acf44c361"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10 OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>Overdosage of pegfilgrastim products may result in leukocytosis and bone pain. Events of edema, dyspnea, and pleural effusion have been reported in a single patient who administered pegfilgrastim on 8 consecutive days in error. In the event of overdose, the patient should be monitored for adverse reactions <content styleCode="italics">[</content>
                     <content styleCode="italics">see <linkHtml href="#LINK_e4516829-3372-4889-a323-a0dffe06c930">Adverse Reactions (6)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250425"/>
            </section>
         </component>
         <component>
            <section ID="LINK_41c29ae9-1b78-468a-a7ea-34de6bf750c1">
               <id root="597d84d2-d5d7-46e0-8375-0489c197fdc0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11  DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Pegfilgrastim-pbbk is a covalent conjugate of recombinant methionyl human G-CSF and monomethoxypolyethylene glycol. Recombinant methionyl human G-CSF is a water-soluble 175 amino acid protein with a molecular weight of approximately 19 kilodaltons (kD). Recombinant methionyl human G-CSF is obtained from the bacterial fermentation of a strain of <content styleCode="italics">E coli</content> transformed with a genetically engineered plasmid containing the human G-CSF gene. To produce pegfilgrastim-pbbk, a 20 kD monomethoxypolyethylene glycol molecule is covalently bound to the N-terminal methionyl residue of recombinant methionyl human G-CSF. The average molecular weight of pegfilgrastim-pbbk is approximately 39 kD. Kanamycin is used during the manufacturing process but is undetectable in the final product.</paragraph>
                  <paragraph>FYLNETRA (pegfilgrastim-pbbk) injection is supplied in 0.6 mL prefilled syringes for manual subcutaneous injection. The prefilled syringe does not bear graduation marks and is designed to deliver the entire contents of the syringe (6 mg/0.6 mL).</paragraph>
                  <paragraph>The delivered 0.6 mL dose from the prefilled syringe contains 6 mg pegfilgrastim-pbbk (based on protein weight) in a sterile, clear, colorless to slightly yellow, preservative-free solution (pH 4.0) containing acetic acid (0.36 mg), polysorbate 20 (0.02 mg), sodium hydroxide (0.03 mg), and sorbitol (30 mg) in Water for Injection, USP.</paragraph>
               </text>
               <effectiveTime value="20250425"/>
            </section>
         </component>
         <component>
            <section ID="LINK_b935b7ce-9ccb-4381-9b54-e0c24be8fbac">
               <id root="77fafe65-a990-4068-a94b-4716ab80c630"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20250425"/>
               <component>
                  <section ID="LINK_3d181282-50a3-41fc-9b54-066bf011c350">
                     <id root="cabdba54-ec9a-4f0a-9faf-7d73388456ee"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d0471174-da0d-4d0a-bc33-c5ff2cd7eb1a">
                     <id root="b5af4191-2373-423f-b87a-b4d0f6f6ef48"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Animal data and clinical data in humans suggest a correlation between pegfilgrastim products’ exposure and the duration of severe neutropenia as a predictor of efficacy. Selection of the dosing regimen of FYLNETRA is based on reducing the duration of severe neutropenia.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f6632b0b-4703-4103-b11f-55e7f153f562">
                     <id root="408decb5-2360-4a56-bb12-5dcd5a7f5526"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of pegfilgrastim was studied in 379 patients with cancer. The pharmacokinetics of pegfilgrastim was nonlinear, and clearance decreased with increases in dose. Neutrophil receptor binding is an important component of the clearance of pegfilgrastim, and serum clearance is directly related to the number of neutrophils. In addition to numbers of neutrophils, body weight appeared to be a factor. Patients with higher body weights experienced higher systemic exposure to pegfilgrastim after receiving a dose normalized for body weight. A large variability in the pharmacokinetics of pegfilgrastim was observed. The half-life of pegfilgrastim ranged from 15 to 80 hours after subcutaneous injection. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Specific Populations</content>
                        </paragraph>
                        <paragraph>No gender-related differences were observed in the pharmacokinetics of pegfilgrastim, and no differences were observed in the pharmacokinetics of geriatric patients (≥ 65 years of age) compared with younger patients (&lt; 65 years of age) <content styleCode="italics">[</content>
                           <content styleCode="italics">see <linkHtml href="#www.splportal.comLINK_3f19635f-4e9f-4316-8666-df712cbe0b78">Use in Specific Populations (8.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Renal Impairment</content>
                        </paragraph>
                        <paragraph>In a study of 30 subjects with varying degrees of renal dysfunction, including end stage renal disease, renal dysfunction had no effect on the pharmacokinetics of pegfilgrastim.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients with Cancer Receiving Myelosuppressive Chemotherapy</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics and safety of pegfilgrastim were studied in 37 pediatric patients with sarcoma in Study 4 <content styleCode="italics">[</content>
                           <content styleCode="italics">see Clinical Studies (14.1)]</content>. The mean (± standard deviation [SD]) systemic exposure (AUC<sub>0-inf</sub>) of pegfilgrastim after subcutaneous administration at 100 mcg/kg was 47.9 (± 22.5) mcg<sup>.</sup>hr/mL in the youngest age group (0 to 5 years, n = 11), 22.0 (± 13.1) mcg·hr/mL in the 6 to 11 years age group (n = 10), and 29.3 (± 23.2) mcg·hr/mL in the 12 to 21 years age group (n = 13). The terminal elimination half-lives of the corresponding age groups were 30.1 (± 38.2) hours, 20.2 (± 11.3) hours, and 21.2 (± 16.0) hours, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Patients Acutely Exposed to Myelosuppressive Doses of Radiation</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"> </content>The pharmacokinetics of pegfilgrastim products is not available in patients acutely exposed to myelosuppressive doses of radiation. Based on limited pharmacokinetic data in irradiated non-human primates, the area under the concentration-time curve (AUC), reflecting the exposure to pegfilgrastim in non-human primates following a 300 mcg/kg dose of pegfilgrastim, appears to be greater than in humans receiving a 6 mg dose. Results from population modeling and simulation indicate that two 6 mg doses of pegfilgrastim administered one week apart in adults result in clinically relevant effects on duration of grade 3 and 4 neutropenia. In addition, weight based dosing in pediatric patients weighing less than 45 kg <content styleCode="italics">[see <linkHtml href="#LINK_6cab6be9-52a8-4ee3-93c0-ccae68b39b4f">Dosage and Administration, Section 2.3, Table 1</linkHtml>] </content>provides exposures comparable to those in adults receiving two 6 mg doses one week apart.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b6526754-9d91-4be0-bf8f-cfa96a145494">
               <id root="1f7c306e-4141-411d-975c-a3009af1b944"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20250425"/>
               <component>
                  <section ID="LINK_c57bdef8-da5d-403b-bf52-de6ad6e903a6">
                     <id root="3a87f3b6-9dce-48d5-a4e3-d55a58fcb247"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No carcinogenicity or mutagenesis studies have been performed with pegfilgrastim products.</paragraph>
                        <paragraph>Pegfilgrastim did not affect reproductive performance or fertility in male or female rats at cumulative weekly doses approximately 6 to 9 times higher than the recommended human dose (based on body surface area).</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_80b68b5a-60d2-429c-9fd5-1cd6d0fe71f9">
               <id root="f7b7fd13-0513-4512-8135-305bf86c6c99"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text/>
               <effectiveTime value="20250425"/>
               <component>
                  <section ID="LINK_70f35532-d0a6-4765-a114-c6afe5a273f4">
                     <id root="3f16e640-fe2f-4947-8614-0c053478eb2f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy</title>
                     <text>
                        <paragraph>Pegfilgrastim was evaluated in three randomized, double-blind, controlled studies. Studies 1 and 2 were active-controlled studies that employed doxorubicin 60 mg/m<sup>2</sup> and docetaxel 75 mg/m<sup>2</sup> administered every 21 days for up to 4 cycles for the treatment of metastatic breast cancer. Study 1 investigated the utility of a fixed dose of pegfilgrastim. Study 2 employed a weight-adjusted dose. In the absence of growth factor support, similar chemotherapy regimens have been reported to result in a 100% incidence of severe neutropenia (ANC &lt; 0.5 x 10<sup>9</sup>/L) with a mean duration of 5 to 7 days and a 30% to 40% incidence of febrile neutropenia. Based on the correlation between the duration of severe neutropenia and the incidence of febrile neutropenia found in studies with filgrastim, duration of severe neutropenia was chosen as the primary endpoint in both studies, and the efficacy of pegfilgrastim was demonstrated by establishing comparability to filgrastim-treated patients in the mean days of severe neutropenia.</paragraph>
                        <paragraph>In Study 1, 157 patients were randomized to receive a single subcutaneous injection of pegfilgrastim (6 mg) on day 2 of each chemotherapy cycle or daily subcutaneous filgrastim (5 mcg/kg/day) beginning on day 2 of each chemotherapy cycle. In Study 2, 310 patients were randomized to receive a single subcutaneous injection of pegfilgrastim (100 mcg/kg) on day 2 or daily subcutaneous filgrastim (5 mcg/kg/day) beginning on day 2 of each chemotherapy cycle.</paragraph>
                        <paragraph>Both studies met the major efficacy outcome measure of demonstrating that the mean days of severe neutropenia of pegfilgrastim-treated patients did not exceed that of filgrastim-treated patients by more than 1 day in cycle 1 of chemotherapy. The mean days of cycle 1 severe neutropenia in Study 1 were 1.8 days in the pegfilgrastim arm compared to 1.6 days in the filgrastim arm [difference in means 0.2 (95% CI - 0.2, 0.6)] and in Study 2 were 1.7 days in the pegfilgrastim arm compared to 1.6 days in the filgrastim arm [difference in means 0.1 (95% CI - 0.2, 0.4)].</paragraph>
                        <paragraph>A secondary endpoint in both studies was days of severe neutropenia in cycles 2 through 4 with results similar to those for cycle 1.</paragraph>
                        <paragraph>Study 3 was a randomized, double-blind, placebo-controlled study that employed docetaxel 100 mg/m<sup>2</sup> administered every 21 days for up to 4 cycles for the treatment of metastatic or non-metastatic breast cancer. In this study, 928 patients were randomized to receive a single subcutaneous injection of pegfilgrastim (6 mg) or placebo on day 2 of each chemotherapy cycle. Study 3 met the major trial outcome measure of demonstrating that the incidence of febrile neutropenia (defined as temperature ≥ 38.2°C and ANC ≤ 0.5 x 10<sup>9</sup>/L) was lower for pegfilgrastim-treated patients as compared to placebo-treated patients (1% versus 17%, respectively, p &lt; 0.001). The incidence of hospitalizations (1% versus 14%) and IV anti-infective use (2% versus 10%) for the treatment of febrile neutropenia was also lower in the pegfilgrastim-treated patients compared to the placebo-treated patients.</paragraph>
                        <paragraph>Study 4 was a multicenter, randomized, open-label study to evaluate the efficacy, safety, and pharmacokinetics <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_f6632b0b-4703-4103-b11f-55e7f153f562">Clinical Pharmacology (12.3)</linkHtml>]</content> of pegfilgrastim in pediatric and young adult patients with sarcoma. Patients with sarcoma receiving chemotherapy age 0 to 21 years were eligible. Patients were randomized to receive subcutaneous pegfilgrastim as a single-dose of 100 mcg/kg (n = 37) or subcutaneous filgrastim at a dose 5 mcg/kg/day (n = 6) following myelosuppressive chemotherapy. Recovery of neutrophil counts was similar in the pegfilgrastim and filgrastim groups. The most common adverse reaction reported was bone pain.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a56f3df3-d9b5-4454-b846-63c97966a36a">
                     <id root="341921fd-6696-4db3-bea4-e81f2bdedcdb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome</title>
                     <text>
                        <paragraph>Efficacy studies of pegfilgrastim products could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Approval of this indication was based on efficacy studies conducted in animals and data supporting pegfilgrastim’s effect on severe neutropenia in patients with cancer receiving myelosuppressive chemotherapy <content styleCode="italics">[see <linkHtml href="#LINK_7d5255b1-436d-4d41-b31c-4be2d16a2c70">Dosage and Administration (2.1)</linkHtml>]</content>. </paragraph>
                        <paragraph>The recommended dose of FYLNETRA is two doses, 6 mg each, administered one week apart for humans exposed to myelosuppressive doses of radiation. For pediatric patients weighing less than 45 kg, dosing of FYLNETRA is weight based and is provided in Table 1 <content styleCode="italics">[see <linkHtml href="#LINK_6cab6be9-52a8-4ee3-93c0-ccae68b39b4f">Dosage and Administration (2.3)</linkHtml>]</content>. This dosing regimen is based on population modeling and simulation analyses. The exposure associated with this dosing regimen is expected to provide sufficient pharmacodynamic activity to treat humans exposed to myelosuppressive doses of radiation <content styleCode="italics">[see <linkHtml href="#LINK_f6632b0b-4703-4103-b11f-55e7f153f562">Clinical Pharmacology (12.3)</linkHtml>]</content>. The safety of pegfilgrastim at a dose of 6 mg has been assessed on the basis of clinical experience in patients with cancer receiving myelosuppressive chemotherapy. </paragraph>
                        <paragraph>The efficacy of pegfilgrastim for the acute radiation syndrome setting was studied in a randomized, placebo-controlled non-human primate model of radiation injury. Rhesus macaques were randomized to either a control (n = 23) or treated (n = 23) cohort. On study day 0, animals (n = 6 to 8 per irradiation day) were exposed to total body irradiation (TBI) of 7.50 ± 0.15 Gy delivered at 0.8 ± 0.03 Gy/min, representing a dose that would be lethal in 50% of animals by 60 days of follow-up (LD50/60). Animals were administered subcutaneous injections of a blinded treatment (control article [5% dextrose in water] or pegfilgrastim [300-319 mcg/kg/day]) on study day 1 and on study day 8. The primary endpoint was survival. Animals received medical management consisting of intravenous fluids, antibiotics, blood transfusions, and other support as required. </paragraph>
                        <paragraph>Pegfilgrastim significantly (at 0.0014 level of significance) increased 60-day survival in irradiated non-human primates: 91% survival (21/23) in the pegfilgrastim group compared to 48% survival (11/23) in the control group.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d4b92fe6-f5f5-48d4-bb2a-c693222b30b7">
               <id root="b9450290-d48b-4578-927b-f22bf9ca09a7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">FYLNETRA single-dose prefilled syringe for manual use </content>
                  </paragraph>
                  <paragraph>FYLNETRA (pegfilgrastim-pbbk) injection is a clear, colorless to slightly yellow, preservative-free solution supplied in a prefilled single-dose syringe for manual use containing 6 mg pegfilgrastim-pbbk, supplied with a 27-gauge, 1/2-inch needle with an UltraSafe Plus<sup>TM</sup> Passive Needle Guard.</paragraph>
                  <paragraph>The needle cap on the prefilled syringe is not made with natural rubber latex.</paragraph>
                  <paragraph>FYLNETRA is provided in a dispensing pack containing one sterile 6 mg/0.6 mL prefilled syringe (NDC 70121-1627-1).</paragraph>
                  <paragraph>FYLNETRA prefilled syringe does not bear graduation marks and is intended only to deliver the entire contents of the syringe (6 mg/0.6 mL) for direct administration. Use of the prefilled syringe is not recommended for direct administration for pediatric patients weighing less than 45 kg who require doses that are less than the full contents of the syringe.</paragraph>
                  <paragraph>Store refrigerated between 36°F to 46°F (2°C to 8°C) in the carton to protect from light. Do not shake. Discard syringes stored at room temperature [68°F to 77°F (20°C to 25°C)] for more than 72 hours. Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard syringe if frozen more than once.</paragraph>
               </text>
               <effectiveTime value="20250425"/>
            </section>
         </component>
         <component>
            <section ID="LINK_7367a80c-6dcd-41e1-99b5-d06097b0ed10">
               <id root="81c35e60-e118-4809-8163-7c4159e6c002"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#www.splportal.comLINK_62113e30-e352-4e4f-8a8a-41a6e25d1091">Patient Information</linkHtml> and <linkHtml href="#www.splportal.comLINK_59f46baf-2458-4d18-a249-2920c7e96789">Instructions for Use</linkHtml>). </paragraph>
                  <paragraph>Advise patients of the following risks and potential risks with FYLNETRA:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Splenic rupture and splenomegaly</item>
                     <item>Acute Respiratory Distress Syndrome</item>
                     <item>Serious allergic reactions</item>
                     <item>Sickle cell crisis</item>
                     <item>Glomerulonephritis</item>
                     <item>Increased risk of Myelodysplastic Syndrome and/or Acute Myeloid Leukemia in patients with breast and lung cancer who receive FYLNETRA in conjunction with chemotherapy and/or radiation therapy</item>
                     <item>Capillary Leak Syndrome</item>
                     <item>Aortitis</item>
                  </list>
                  <paragraph>Advise patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome) that efficacy studies of pegfilgrastim products for this indication could not be conducted in humans for ethical and feasibility reasons and that, therefore, approval of this use was based on efficacy studies conducted in animals <content styleCode="italics">[see <linkHtml href="#LINK_a56f3df3-d9b5-4454-b846-63c97966a36a">Clinical Studies (14.2)</linkHtml>]</content>.</paragraph>
                  <paragraph>Instruct patients who self-administer FYLNETRA using the single-dose prefilled syringe of the:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Importance of following the Instructions for Use.</item>
                     <item>Dangers of reusing syringes.</item>
                     <item>Importance of following local requirements for proper disposal of used syringes.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>Manufactured by: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Kashiv BioSciences, LLC</content>
                  </paragraph>
                  <paragraph>Piscataway, NJ 08854</paragraph>
                  <paragraph>US License No. 2131</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <paragraph>Bridgewater, NJ 08807</paragraph>
                  <paragraph>Rev. 04-2025-02</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>LBL-0003</paragraph>
               </text>
               <effectiveTime value="20250425"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>logo</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_62113e30-e352-4e4f-8a8a-41a6e25d1091">
               <id root="f8f67661-68ac-4100-af4e-77fb33abff8b"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>PATIENT INFORMATION</title>
               <text>
                  <table>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode=" Toprule Lrule Rrule">
                              <br/>
                              <paragraph>
                                 <content styleCode="bold">FYLNETRA<sup>®</sup> (fil-ne-trah)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(pegfilgrastim-pbbk)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">injection</content>
                              </paragraph>
                              <content styleCode="bold">
                                 <content styleCode="bold">Single-Dose Prefilled Syringe</content>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is</content>
                                 <content styleCode="bold"> FYLNETRA?</content>
                              </paragraph>
                              <paragraph>FYLNETRA is a man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body’s fight against infection.</paragraph>
                              <paragraph>Acute Radiation Syndrome: The effectiveness of pegfilgrastim for this use was only studied in animals, because it could not be studied in people.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">
                                 <content styleCode="bold">Do not take </content>
                                 <content styleCode="bold">FYLNETRA </content>
                              </content>if you have had a serious allergic reaction to pegfilgrastim products or filgrastim products.</td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before you receive</content>
                                 <content styleCode="bold"> FYLNETRA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have a sickle cell disorder.</item>
                                 <item>have kidney problems.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if FYLNETRA will harm your unborn baby.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if FYLNETRA passes into your breast milk.</item>
                              </list>
                              <content styleCode="bold">
                                 <content styleCode="bold">Tell your healthcare provider about all of the medicines you take</content>,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How will I receive</content>
                                 <content styleCode="bold"> FYLNETRA?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">FYLNETRA is given as an injection under your skin (subcutaneous injection) by a healthcare provider. If your healthcare provider decides that the subcutaneous injections can be given at home by you or your caregiver, follow the detailed “Instructions for Use” that comes with your FYLNETRA for information on how to prepare and inject a dose of FYLNETRA.</content>
                                 </item>
                                 <item>You and your caregiver will be shown how to prepare and inject FYLNETRA before you use it.</item>
                                 <item>You should not inject a dose of FYLNETRA to children weighing less than 45 kg from a FYLNETRA prefilled syringe. A dose less than 0.6 mL (6 mg) cannot be accurately measured using the FYLNETRA prefilled syringe.</item>
                                 <item>If you are receiving FYLNETRA because you are also receiving chemotherapy, the last dose of FYLNETRA should be injected at least 14 days before and 24 hours after your dose of chemotherapy.</item>
                                 <item>If you miss a dose of FYLNETRA, talk to your healthcare provider about when you should give your next dose.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of</content>
                                 <content styleCode="bold"> FYLNETRA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">FYLNETRA may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Spleen rupture. </content> Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder.</item>
                                 <item>
                                    <content styleCode="bold">A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). </content>Call your healthcare provider or get emergency help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.</item>
                                 <item>
                                    <content styleCode="bold">Serious allergic reactions.</content> FYLNETRA can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using FYLNETRA and call your healthcare provider or get emergency medical help right away.</item>
                                 <item>
                                    <content styleCode="bold">Sickle cell crises.</content> You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive FYLNETRA. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.</item>
                                 <item>
                                    <content styleCode="bold">Kidney injury (glomerulonephritis).</content> FYLNETRA can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms.</item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>swelling of your face or ankles</item>
                                 <item>blood in your urine or dark colored urine</item>
                                 <item>you urinate less than usual</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Increased white blood cell count (leukocytosis)</content>. Your healthcare provider will check your blood during treatment with FYLNETRA.</item>
                                 <item>
                                    <content styleCode="bold">Decreased platelet count (thrombocytopenia)</content>. Your healthcare provider will check your blood during treatment with FYLNETRA. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with FYLNETRA. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.</item>
                                 <item>
                                    <content styleCode="bold">Capillary Leak Syndrome</content>. FYLNETRA can cause fluid to leak from blood vessels into your body’s tissues. This condition is called “Capillary Leak Syndrome” (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:</item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>swelling or puffiness and are urinating less than usual</item>
                                 <item>trouble breathing</item>
                                 <item>swelling of your stomach area (abdomen) and feeling of fullness</item>
                                 <item>dizziness or feeling faint</item>
                                 <item>a general feeling of tiredness</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Myelodysplastic syndrome and acute myeloid leukemia.  </content>If you have breast cancer or lung cancer, when FYLNETRA is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with FYLNETRA.</item>
                                 <item>
                                    <content styleCode="bold">Inflammation of the aorta (aortitis).</content> Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received pegfilgrastim products.  Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms. </item>
                              </list>
                              <paragraph>The most common side effects of FYLNETRA are pain in the bones, arms, and legs.</paragraph>
                              <paragraph>These are not all the possible side effects of FYLNETRA.</paragraph>
            Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store </content>
                                 <content styleCode="bold">FYLNETRA?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store FYLNETRA in the refrigerator between 36°F to 46°F (2°C to 8°C).</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> freeze. If FYLNETRA is accidentally frozen, allow the prefilled syringe to thaw in the refrigerator before injecting.</item>
                                 <item>
                                    <content styleCode="bold">Do not </content>use a FYLNETRA prefilled syringe that has been frozen more than 1 time. Use a new FYLNETRA prefilled syringe. </item>
                                 <item>Keep the prefilled syringe in the original carton to protect from light or physical damage.</item>
                                 <item>Do not shake the prefilled syringe.</item>
                                 <item>Take FYLNETRA out of the refrigerator 30 minutes before use and allow it to reach room temperature before preparing an injection.</item>
                                 <item>Throw away (dispose of) any FYLNETRA that has been left at room temperature, 68°F to 77°F (20°C to 25°C), for more than 72 hours.</item>
                              </list>
                              <content styleCode="bold">
                                 <content styleCode="bold">Keep the </content>
                                 <content styleCode="bold">FYLNETRA </content>
                                 <content styleCode="bold">prefilled syringe out of the reach of children.</content>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of </content>
                                 <content styleCode="bold">FYLNETRA.</content>
                              </paragraph>
            Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.  Do not use FYLNETRA for a condition for which it was not prescribed.  Do not give FYLNETRA to other people, even if they have the same symptoms that you have. It may harm them.  You can ask your pharmacist or healthcare provider for information about FYLNETRA that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in</content>
                                 <content styleCode="bold">FYLNETRA?</content>
                              </paragraph>
                              <paragraph>Active ingredient: pegfilgrastim-pbbk</paragraph>
                              <paragraph>Inactive ingredients: acetic acid, polysorbate 20, sodium hydroxide and sorbitol in water for injection.</paragraph>
                              <paragraph>Manufactured by:<content styleCode="bold"> Kashiv BioSciences, LLC,</content> Piscataway, NJ 08854</paragraph>
                              <paragraph>US License No. 2131</paragraph>
                              <paragraph>Distributed by:<content styleCode="bold"> Amneal Pharmaceuticals LLC,</content> Bridgewater, NJ 08807</paragraph>
            For more information, go to www.fylnetra.us or call 1-877-835-5472.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.                                                                                                          Rev. 04-2025-02</paragraph>
               </text>
               <effectiveTime value="20250425"/>
            </section>
         </component>
         <component>
            <section ID="LINK_59f46baf-2458-4d18-a249-2920c7e96789">
               <id root="1155bce3-2ce2-4652-9249-3b207ca8f81d"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>
                  <content styleCode="bold">Instructions for Use </content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Instructions for Use<br/>
                     </content>
                     <content styleCode="bold">FYLNETRA<sup>®</sup> (fil-ne-trah)<br/>
                     </content>
                     <content styleCode="bold">(pegfilgrastim-pbbk)<br/>
                     </content>
                     <content styleCode="bold">Injection, for subcutaneous use<br/>
                     </content>Single-Dose Prefilled Syringe</paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">Guide to parts</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> <renderMultiMedia referencedObject="MM2"/>
                     </content> </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">Important: </content>The needle is covered by the gray needle cap before use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>Read the Patient Information for important information you need to know about FYLNETRA before using these Instructions for Use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Before you use a FYLNETRA prefilled syringe, read this important information.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">Storing the prefilled syringe</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store FYLNETRA in the refrigerator between 36°F to 46°F (2°C to 8°C).</item>
                     <item>
                        <content styleCode="bold">Do not </content>freeze.</item>
                     <item>Keep the prefilled syringe in the original pack to protect from light or physical damage.</item>
                     <item>Take the prefilled syringe out of the refrigerator 30 minutes before use and allow it to reach room temperature before preparing an injection.</item>
                     <item>Throw away (dispose of) any FYLNETRA that has been at left at room temperature, 68°F to 77°F (20°C to 25°C), for more than 72 hours.</item>
                     <item>Keep the FYLNETRA prefilled syringe out of the reach of children.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Using the prefilled syringe</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">It is important that you do not try to give the injection unless you or your caregiver has received training from your healthcare provider.</content>
                     </item>
                     <item>Make sure the name FYLNETRA appears on the pack and prefilled syringe label.</item>
                     <item>Check the pack and prefilled syringe label to make sure the dose strength is 6 mg/0.6 mL.</item>
                     <item>You should not inject a dose of FYLNETRA to children weighing less than 45 kg from a FYLNETRA prefilled syringe. A dose less than 0.6 mL (6 mg) cannot be accurately measured using the FYLNETRA prefilled syringe.</item>
                     <item>
                        <content styleCode="bold">Do not </content>use a prefilled syringe after the expiration date on the label.</item>
                     <item>
                        <content styleCode="bold">Do not </content>shake the prefilled syringe.</item>
                     <item>
                        <content styleCode="bold">Do not </content>remove the gray needle cap from the prefilled syringe until you are ready to inject.</item>
                     <item>
                        <content styleCode="bold">Do not </content>use the prefilled syringe if the pack is open or damaged.</item>
                     <item>
                        <content styleCode="bold">Do not </content>use a prefilled syringe if it has been dropped on a hard surface. The prefilled syringe may be broken even if you cannot see the break. Use a new prefilled syringe.</item>
                     <item>
                        <content styleCode="bold">Do not </content>attempt to activate the needle safety guard prior to injection.</item>
                  </list>
                  <paragraph>Call your healthcare provider if you or your caregiver have any questions.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 1: Prepare</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">A. </content>Remove the prefilled syringe pack from the refrigerator.</paragraph>
                  <paragraph>Put the original pack with any unused prefilled syringes back in the refrigerator.</paragraph>
                  <paragraph>Remove the syringe tray from the pack. On a clean, well-lit surface, place the syringe tray at room temperature for <content styleCode="bold">30 </content>minutes before you give an injection.</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Do not </content>use the prefilled syringe if the pack is damaged.</item>
                     <item>
                        <content styleCode="bold">Do not </content>try to warm the prefilled syringe by using a heat source such as hot water or microwave.</item>
                     <item>
                        <content styleCode="bold">Do not </content>leave the prefilled syringe in direct sunlight.</item>
                     <item>
                        <content styleCode="bold">Do not </content>shake the prefilled syringe.</item>
                  </list>
                  <paragraph>Open the tray by peeling away the cover. Grab the clear safety guard to remove the prefilled syringe from the tray.</paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph>For safety reasons:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Do not </content>grab the plunger rod.</item>
                     <item>
                        <content styleCode="bold">Do not </content>grab the gray needle cap.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">B. </content>Inspect the medicine and prefilled syringe.</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <paragraph>
                     <content styleCode="bold">Make sure the medicine in the prefilled syringe is clear and colorless.</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Do not </content>use the prefilled syringe if:</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>The medicine is cloudy or discolored, or contains flakes or particles</item>
                     <item>Any part appears cracked or broken</item>
                     <item>The prefilled syringe has been dropped</item>
                     <item>The gray needle cap is missing or not securely attached.</item>
                     <item>The expiration date printed on the label has passed.</item>
                  </list>
                  <paragraph>In all cases, use a new prefilled syringe and call your healthcare provider.</paragraph>
                  <paragraph>
                     <content styleCode="bold">C </content>Gather all materials needed for the injection.</paragraph>
                  <paragraph>Wash your hands thoroughly with soap and water.</paragraph>
                  <paragraph>On a clean, well-lit work surface place the:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Prefilled syringe</item>
                     <item>Alcohol wipe</item>
                     <item>Cotton ball or gauze pad</item>
                     <item>Adhesive bandage</item>
                     <item>Sharps disposal container</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">Step 2: Get ready</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">D </content>Prepare and clean the injection site(s).</paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM6"/>
                     </content> </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">You can use</content>:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Thigh</item>
                     <item>Stomach area (abdomen), except for a <content styleCode="bold">2</content>-inch area around the navel (belly button)</item>
                     <item>Upper outer area of the buttocks (only if someone else is giving you the injection)</item>
                     <item>Outer area of upper arm (only if someone else is giving you the injection)</item>
                  </list>
                  <paragraph>Clean the injection site with an alcohol wipe. Let the skin dry.</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Do not </content>touch this area again before injecting.</item>
                     <item>If you want to use the same injection site, make sure it is not the same spot on the injection site you used for a previous injection.</item>
                     <item>
                        <content styleCode="bold">Do not </content>inject into areas where the skin is tender, bruised, red, or hard. Avoid injecting into areas with scars or stretch marks.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">E </content>Hold the prefilled syringe by the barrel. Carefully pull the gray needle cap straight off and away from the body.</paragraph>
                  <paragraph> <renderMultiMedia referencedObject="MM7"/>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Do not </content>remove the gray needle cap from the prefilled syringe until you are ready to inject.</item>
                     <item>
                        <content styleCode="bold">Do not </content>twist or bend the gray needle cap.</item>
                     <item>
                        <content styleCode="bold">Do not </content>hold the prefilled syringe by the plunger rod.</item>
                     <item>
                        <content styleCode="bold">Do not </content>put the gray needle cap back onto the prefilled syringe.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">Important</content>: Throw the gray needle cap into the sharps disposal container.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 3: Subcutaneous (under the skin) injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">F </content>Pinch the injection site to create a firm surface.</paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">Important: </content>Keep skin pinched while injecting.</paragraph>
                  <paragraph>
                     <content styleCode="bold">G </content>Hold the pinch. Insert the needle into the skin at 45 to 90 degrees.</paragraph>
                  <renderMultiMedia referencedObject="MM9"/>
                  <paragraph>
                     <content styleCode="bold">H </content>Using slow and constant pressure, push the plunger rod until it reaches the bottom and the plunger head is completely between the needle guard wings.</paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM10"/>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important: </content>When you remove the syringe, if it looks like the medicine is still in the syringe barrel, this means you have not received a full dose. Call your healthcare provider right away.</paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 4: Finish</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">I  </content>
                     <renderMultiMedia referencedObject="MM11"/>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">Before you finish!</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>While you continue to hold the syringe, slowly let go of the plunger head.</item>
                     <item>As you let go of the plunger head, the needle will automatically slide into the clear safety guard until the needle is completely covered.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM12"/>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important</content>: If the clear safety guard does not activate after Step I, remove the needle from the skin and throw away (discard of) the used prefilled syringe as instructed in Step J right away.</paragraph>
                  <paragraph>Keep your hands away from the needle at all times.</paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">J </content>Discard (throw away) the used prefilled syringe</paragraph>
                  <renderMultiMedia referencedObject="MM13"/>
                  <list listType="unordered" styleCode="Disc">
                     <item>Put the used prefilled syringe in a FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not </content>throw away (dispose of) the syringe in the household trash.</item>
                     <item>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>made of a heavy-duty plastic,</item>
                     <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</item>
                     <item>upright and stable during use,</item>
                     <item>leak-resistant, and</item>
                     <item>properly labeled to warn of hazardous waste inside the container.</item>
                  </list>
                  <list listType="unordered" styleCode="Disc">
                     <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at http://www.fda.gov/safesharpsdisposal</item>
                     <item>
                        <content styleCode="bold">Do not </content>reuse the prefilled syringe.</item>
                     <item>
                        <content styleCode="bold">Do not </content>recycle the prefilled syringe or sharps disposal container or throw them into the household trash.<br/>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Important</content>: Always keep the sharps disposal container out of the reach of children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">K Examine the injection site.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>If there is blood, press a cotton ball or gauze pad on the injection site. <content styleCode="bold">Do not </content>rub the injection site. Apply an adhesive bandage if needed.</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Kashiv BioSciences, LLC</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>Piscataway, NJ 08854</paragraph>
                  <paragraph>US License No. 2131</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>Bridgewater, NJ 08807</paragraph>
                  <paragraph>Rev. 05-2022-00</paragraph>
               </text>
               <effectiveTime value="20250425"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>figure a</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>figure c</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>figure d</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>figure e</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>figure f</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>figure g-h</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>figure i</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>figure j</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>figure k</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>figure l-stop</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>figure m</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>figure n</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_a8f7c6ff-8b48-4b52-a5f1-5adf1264a8cc">
               <id root="3e3b0117-5a7f-46b2-a4d4-b7bd455a7147"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <renderMultiMedia referencedObject="MM14"/>
               </text>
               <effectiveTime value="20250425"/>
               <component>
                  <observationMedia ID="MM14">
                     <text>carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fylnetra-pegfilgrastim-pbbk-injection-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section ID="LINK_c5b52efa-3266-43fe-aff3-7193b85535c0">
                     <id root="0ae0e9fe-4019-46ab-89af-ad3180969572"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <renderMultiMedia referencedObject="MM15"/>
                     </text>
                     <effectiveTime value="20250425"/>
                     <component>
                        <observationMedia ID="MM15">
                           <text>lidding</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="fylnetra-pegfilgrastim-pbbk-injection-15.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3d09ea28-2685-4442-83b9-bac30fe1d01e">
                     <id root="f3951090-3503-4e3d-93d2-20c20f454c26"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <renderMultiMedia referencedObject="MM16"/>
                     </text>
                     <effectiveTime value="20250425"/>
                     <component>
                        <observationMedia ID="MM16">
                           <text>label</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="fylnetra-pegfilgrastim-pbbk-injection-16.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>